Actively Recruiting

Phase 1
Age: 12Months - 18Years
All Genders
NCT06567769

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Led by GC Biopharma Corp · Updated on 2025-08-28

9

Participants Needed

5

Research Sites

131 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).

CONDITIONS

Official Title

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Who Can Participate

Age: 12Months - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with documented MPS IIIA diagnosis
  • Participants aged 6 12 months and 4 18 years
Not Eligible

You will not qualify if you...

  • Participants with significant non-MPS IIIA related central nervous system impairment
  • Participants with previous complication from intraventricular drug administration
  • Participants with contraindications for MRI scans and for neurosurgery
  • Participants that received treatment with any investigational drug or a device intended as a treatment for MPS IIIA within 30 days or 5 half-lives prior to the study
  • Participants that received a hematopoietic stem cell or bone marrow transplant or received gene therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

UCSF Benioff Children's Hospital

Oakland, California, United States, 94609

Actively Recruiting

2

University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

3

National Center for Child Health and Development

Setagaya City, Tokyo, Japan

Actively Recruiting

4

Ajou University Medical Center

Suwon, Gyeongi-do, South Korea

Actively Recruiting

5

Samsung Medical Center

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

G

GC Biopharma Corp.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | DecenTrialz